Lifeward Stock Secures $1.00 Minimum Bid for 10 Days, Nasdaq Compliance Restored
Lifeward’s common stock maintained a minimum closing bid of $1.00 or more for ten consecutive business days through March 9, 2026, satisfying Nasdaq Listing Rule 5550(a)(2). Nasdaq has closed the prior bid price deficiency matter and will continue listing Lifeward shares on the Nasdaq Capital Market.
1. Regaining Nasdaq Compliance
Lifeward’s common stock attained a minimum closing bid price of $1.00 or more for ten consecutive business days, satisfying Nasdaq Listing Rule 5550(a)(2) on March 9, 2026. This achievement closes the prior deficiency notification and restores the company’s compliance status with Nasdaq requirements.
2. Continued Listing on Nasdaq Capital Market
With the deficiency matter closed, Lifeward ordinary shares will remain listed and traded on the Nasdaq Capital Market without further restrictions. This outcome prevents potential delisting and supports uninterrupted trading and investor access.
3. Company Overview and Market Position
Lifeward develops and commercializes rehabilitation products—such as the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System and ReStore Exo-Suit—to serve individuals with physical limitations. Operating in the U.S., Israel and Germany, the company’s portfolio spans clinical, home and community settings.